Barclays Initiates Merck Coverage with Overweight Rating on 2026 Drug Pipeline
Feb 20, 2026
Barclays initiated coverage on Merck with an overweight rating and $140 price target, citing expected product launches including enlicitide and pivotal trial readouts for tulisokibart in 2026.